Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1995 Mar;71(3):633–636. doi: 10.1038/bjc.1995.124

Symptoms at presentation for treatment in patients with lung cancer: implications for the evaluation of palliative treatment. The Medical Research Council (MRC) Lung Cancer Working Party.

P Hopwood 1, R J Stephens 1
PMCID: PMC2033650  PMID: 7533520

Abstract

The ten most frequently reported pretreatment symptoms on the Rotterdam Symptom Checklist, which was completed by more than 650 patients entering two MRC Lung Cancer Working Party multicentre randomised trials, included general symptoms (tiredness, lack of appetite) and psychological distress (worry, anxiety) in addition to disease-related chest symptoms (cough, shortness of breath). Although the number and severity of symptoms increased with worsening performance status, the commonest symptoms were found to be virtually the same for patients with small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC), and for different grades of performance status. Women with NSCLC reported more psychological symptoms than males, but this difference was much less evident in patients with SCLC. Thus, in order to assess fully the benefit of palliative treatments in patients with lung cancer, account must be taken of all symptoms at presentation, in addition to the traditionally recognised chest symptoms.

Full text

PDF
633

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Cullen M. H., Joshi R., Chetiyawardana A. D., Woodroffe C. M. Mitomycin, ifosfamide and cis-platin in non-small cell lung cancer: treatment good enough to compare. Br J Cancer. 1988 Sep;58(3):359–361. doi: 10.1038/bjc.1988.219. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Curtis E. B., Krech R., Walsh T. D. Common symptoms in patients with advanced cancer. J Palliat Care. 1991 Summer;7(2):25–29. [PubMed] [Google Scholar]
  3. Earl H. M., Rudd R. M., Spiro S. G., Ash C. M., James L. E., Law C. S., Tobias J. S., Harper P. G., Geddes D. M., Eraut D. A randomised trial of planned versus as required chemotherapy in small cell lung cancer: a Cancer Research Campaign trial. Br J Cancer. 1991 Sep;64(3):566–572. doi: 10.1038/bjc.1991.351. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Fernandez C., Rosell R., Abad-Esteve A., Monras P., Moreno I., Serichol M., Roviralta M. Quality of life during chemotherapy in non-small cell lung cancer patients. Acta Oncol. 1989;28(1):29–33. doi: 10.3109/02841868909111177. [DOI] [PubMed] [Google Scholar]
  5. Geddes D. M., Dones L., Hill E., Law K., Harper P. G., Spiro S. G., Tobias J. S., Souhami R. L. Quality of life during chemotherapy for small cell lung cancer: assessment and use of a daily diary card in a randomized trial. Eur J Cancer. 1990 Apr;26(4):484–492. doi: 10.1016/0277-5379(90)90022-l. [DOI] [PubMed] [Google Scholar]
  6. Holli K., Hakama M. Biological, physical, mental and social dimensions of breast cancer: information based on routine case notes. Eur J Cancer. 1993;29A(15):2152–2155. doi: 10.1016/0959-8049(93)90052-h. [DOI] [PubMed] [Google Scholar]
  7. Kaasa S., Mastekaasa A., Lund E. Prognostic factors for patients with inoperable non-small cell lung cancer, limited disease. The importance of patients' subjective experience of disease and psychosocial well-being. Radiother Oncol. 1989 Jul;15(3):235–242. doi: 10.1016/0167-8140(89)90091-1. [DOI] [PubMed] [Google Scholar]
  8. Mor V., Laliberte L., Morris J. N., Wiemann M. The Karnofsky Performance Status Scale. An examination of its reliability and validity in a research setting. Cancer. 1984 May 1;53(9):2002–2007. doi: 10.1002/1097-0142(19840501)53:9<2002::aid-cncr2820530933>3.0.co;2-w. [DOI] [PubMed] [Google Scholar]
  9. Muers M. F., Round C. E. Palliation of symptoms in non-small cell lung cancer: a study by the Yorkshire Regional Cancer Organisation Thoracic Group. Thorax. 1993 Apr;48(4):339–343. doi: 10.1136/thx.48.4.339. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Osoba D. Lessons learned from measuring health-related quality of life in oncology. J Clin Oncol. 1994 Mar;12(3):608–616. doi: 10.1200/JCO.1994.12.3.608. [DOI] [PubMed] [Google Scholar]
  11. Richards M. A., Hopwood P., Ramirez A. J., Twelves C. J., Ferguson J., Gregory W. M., Swindell R., Scrivener W., Miller J., Howell A. Doxorubicin in advanced breast cancer: influence of schedule on response, survival and quality of life. Eur J Cancer. 1992;28A(6-7):1023–1028. doi: 10.1016/0959-8049(92)90447-a. [DOI] [PubMed] [Google Scholar]
  12. Sarna L. Women with lung cancer: impact on quality of life. Qual Life Res. 1993 Feb;2(1):13–22. doi: 10.1007/BF00642885. [DOI] [PubMed] [Google Scholar]
  13. Schipper H., Clinch J., McMurray A., Levitt M. Measuring the quality of life of cancer patients: the Functional Living Index-Cancer: development and validation. J Clin Oncol. 1984 May;2(5):472–483. doi: 10.1200/JCO.1984.2.5.472. [DOI] [PubMed] [Google Scholar]
  14. Simes R. J. Risk-benefit relationships in cancer clinical trials: the ECOG experience in non-small-cell lung cancer. J Clin Oncol. 1985 Apr;3(4):462–472. doi: 10.1200/JCO.1985.3.4.462. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES